DOCSLIB.ORG

Therapeutic Potential of Vasopressin-Receptor Antagonists in Heart Failure

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Therapeutic Potential of Vasopressin-Receptor Antagonists in Heart Failure J Pharmacol Sci 124, 1 – 6 (2014) Journal of Pharmacological Sciences © The Japanese Pharmacological Society Current Perspective Therapeutic Potential of Vasopressin-Receptor Antagonists in Heart Failure Yasukatsu Izumi1,*, Katsuyuki Miura2, and Hiroshi Iwao1 1Department of Pharmacology, 2Applied Pharmacology and Therapeutics, Osaka City University Medical School, Osaka 545-8585, Japan Received October 2, 2013; Accepted November 17, 2013 Abstract. Arginine vasopressin (AVP) is a 9-amino acid peptide that is secreted from the posterior pituitary in response to high plasma osmolality and hypotension. AVP has important roles in circulatory and water homoeostasis, which are mediated by oxytocin receptors and by AVP receptor subtypes: V1a (mainly vascular), V1b (pituitary), and V2 (renal). Vaptans are orally and intravenously active nonpeptide vasopressin-receptor antagonists. Recently, subtype-selective nonpeptide vasopressin-receptor agonists have been developed. A selective V1a-receptor antago- nist, relcovaptan, has shown initial positive results in the treatment of Raynaud’s disease, dysmen- orrhea, and tocolysis. A selective V1b-receptor antagonist, nelivaptan, has beneficial effects in the treatment of psychiatric disorders. Selective V2-receptor antagonists including mozavaptan, lixivaptan, satavaptan, and tolvaptan induce highly hypotonic diuresis without substantially affecting the excretion of electrolytes. A nonselective V1a/V2-receptor antagonist, conivaptan, is used in the treatment for euvolaemic or hypervolemic hyponatremia. Recent basic and clinical studies have shown that AVP-receptor antagonists, especially V2-receptor antagonists, may have therapeutic potential for heart failure. This review presents current information about AVP and its antagonists. Keywords: arginine vasopressin, diuretic, heart failure, vasopressin receptor antagonist 1. Introduction receptor blockers, diuretics, b-adrenoceptor blockers, digitalis glycosides, and inotropic agents (4). Unfortu- The prevalence of heart failure has increased in the nately, they are not enough to reduce mortality. Further- past several decades (1), and congestive heart failure has more, therapeutic options in acute decompensated now emerged as a major public health hazard with grave heart failure have not changed significantly over the implications. Rosamond et al. reported that 2.5% of the past several decades despite advances in the management adult American population (approximately 5.3 million of chronic heart failure. Therefore, the discovery of men and women) suffer from congestive heart failure, novel agents is needed for successful treatment of heart and the medical costs of heart failure in the United States failure. are estimated at approximately $60 billion per year (2). Despite advanced medical care for patients with heart 2. Vasopressin in heart failure failure, the average 5-year survival is about 50% (3). Currently, various types of therapeutic agents are used Arginine vasopressin (AVP) is secreted from the for chronic heart failure as standard treatment, including posterior pituitary in response to elevation in plasma angiotensin-converting enzyme inhibitors, angiotensin- osmolality and decreases in arterial pressure. AVP plays a key role in maintaining both volume homeostasis via *Corresponding author. [email protected] osmotic AVP V2 receptor expressed on the basolateral Published online in J-STAGE on January 7, 2014 doi: 10.1254/jphs.13R13CP membranes of the renal collecting duct principal cells and vascular tone via nonosmotic AVP V1a receptor Invited article expressed in vascular smooth muscle cells (5). 1 2 Y Izumi et al Fig. 1. Effects of individual subtypes of arginine vasopressin receptors. Three subtypes of AVP receptors have been identified has detrimental effect in patients with heart failure so far, which belong to rhodopsin-like G-protein–coupled because it leads to increased congestion, while hypo- receptors (6). The role of each AVP receptor subtype in natremia is associated with increased mortality (12). the pathogenesis of heart failure is shown in Fig. 1. The Intravenous infusion of AVP in patients with heart V1a receptor is found on vascular smooth muscle cells, failure increases systemic vascular resistance and pulmo- hepatocytes, and platelets. Binding of AVP to the V1a nary capillary wedge pressure, while it decreases stroke receptor activates Gq/phospholipase C-b, which results volume and cardiac output. These changes were thought in an increase in intracellular calcium levels and activa- to result from AVP-induced vasoconstriction mediated tion of protein kinase C (5, 7), leading to vasoconstric- by the V1a receptor because no association with alterna- tion, platelet aggregation, and growth of the smooth tion in blood pressure or heart rate was observed (13). muscle cells. Furthermore, stimulation of the V1a receptor is associated The V2 receptor is mainly located on the basolateral with the development of cardiac hypertrophy in experi- membrane of the collecting ducts in the renal medulla mental animal models (14). Thus, chronic AVP stimula- (6). Binding of AVP to the V2 receptor activates adenyl- tion could promote cardiac remodeling similarly to other ate cyclase via Gs protein, which leads to an increase in neurohormonal systems. Elevated AVP levels activate intracellular cyclic adenosine monophosphate (cAMP) the V2 receptor, increase the expression of AQP chan- (7). Elevation of intracellular cAMP facilitates transloca- nels, and cause water retention. As a result, preload and tion of aquaporin (AQP) channels from intracellular pulmonary capillary wedge pressure are increased. vesicles to the apical plasma membrane through activa- tion of protein kinase A, leading to an increase in water 3. Vasopressin-receptor antagonists in heart failure permeability (8). The V1b (V3) receptor is found predominantly in the Selective AVP V2-receptor antagonists induce hypo- anterior pituitary, where it mediates adrenocorticotropin tonic diuresis without substantially affecting the excre- release. It is still unknown what role the V1b receptor tion of electrolytes. Tolvaptan and lixivaptan, V2- plays in heart failure. selective antagonists with KiV2:KiV1a binding affinities Previous studies have documented the presence of of 29:1 and 100:1 in human cells, respectively, have been elevated AVP levels in patients with heart failure extensively studied in clinical trials and experimental (9 – 10). In addition, an increase in AVP levels has been animal models of heart failure. A small, randomized, associated with increasing severity of heart failure (9). placebo-controlled, crossover study showed a similar The increase in AVP levels results in impaired excretion urine output in stable patients with heart failure with of free water in patients with heart failure due to an preserved renal function who received single doses of a increase in the number of AQP channels in the collecting loop diuretic (furosemide, 80 mg) or tolvaptan (30 mg) duct (8). This results not only in abnormal water (15). There was no difference in the glomerular filtration retention but also in hyponatremia (11). Water retention rate between the two agents, although furosemide Role of Vasopressin in Heart Failure 3 Table 1. Recent clinical trials using AVP antagonists in heart failure AVP Reference Design, Setting, and Participants Effect antagonist No. V2-selective antagonist Tolvaptan Randomized, double-blind, placebo-controlled, parallel-group, dose-ranging, · Increase in the net fluid loss, decrease in body (Oral) phase 2 trial conducted at 45 centers in the United States and Argentina weight, and improvement in the rate of and enrolling 319 patients with left ventricular ejection fraction of less worsening heart failure. 18 than 40% and hospitalized for heart failure with persistent signs and · No adverse effects such as changes in blood symptoms of systemic congestion despite standard therapy. pressure, heart rate, or electrolytes. Tolvaptan Two identical prospective, randomized, double-blind, placebo-controlled · Improvement in body weight, peripheral (Oral) trials at 359 sites in North America, South America, and Europe were edema, and patient-assessed dyspnea. conducted during the inpatient period of the Efficacy of Vasopressin · No changes in morbidity or mortality. 19 Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST). A total of 4133 patients hospitalized with heart failure and congestion were studied. Tolvaptan A total of 181 patients with advanced heart failure on standard therapy · Increase in urine output and serum sodium (Oral) were randomized to double-blind treatment with tolvaptan at a single oral levels in a dose-dependent manner. dose (15, 30, or 60 mg) or placebo. · No changes in blood pressure, heart rate, 20 systemic and pulmonary vascular resistance, or cardiac index. Tolvaptan Patients with heart failure, systolic dysfunction, and signs of congestion · Reduction in body weight. Well tolerability. (Oral) were removed from baseline diuretic therapy and placed on a low-sodium · No changes in serum electrolytes, other diet. After a 2-day run-in period, 83 patients were randomized to placebo laboratory values, or blood pressure. 21 (n = 21), mono therapy with tolvaptan 30 mg (n = 20), monotherapy with furosemide 80 mg (n = 22) or combination therapy with both agents (n = 20) once daily for 7 days. Lixivaptan The effects of lixivaptan in 42 diuretic-requiring patients with mild-to- · Increase in urine output in a
Load more

Recommended publications
  • Neural Basis for Regulation of Vasopressin Secretion by Presystemic Anticipated Disturbances in Osmolality, and by Hypoglycemia
    Neural Basis for Regulation of Vasopressin Secretion by Presystemic Anticipated Disturbances in Osmolality, and by Hypoglycemia The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Kim, Angela. 2020. Neural Basis for Regulation of Vasopressin Secretion by Presystemic Anticipated Disturbances in Osmolality, and by Hypoglycemia. Doctoral dissertation, Harvard University, Graduate School of Arts & Sciences. Citable link https://nrs.harvard.edu/URN-3:HUL.INSTREPOS:37365939 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Neural Basis for Regulation of Vasopressin Secretion by Presystemic Anticipated Disturbances in Osmolality, and by Hypoglycemia A dissertation presented by Angela Kim to The Division of Medical Sciences in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the subject of Neuroscience Harvard University Cambridge, Massachusetts April 2020 © 2020 Angela Kim All rights reserved. Dissertation Advisor: Bradford B. Lowell Angela Kim Neural Basis for Regulation of Vasopressin Secretion by Presystemic Anticipated Disturbances in Osmolality, and by Hypoglycemia Abstract Vasopressin (AVP), released by magnocellular AVP neurons of the hypothalamus, is a multifaceted hormone. AVP regulates many physiological processes including blood osmolality, blood glucose, and blood pressure. In this dissertation, I present two independent studies investigating the neural mechanism for role of AVP in fluid and glucose homeostasis. In regards to regulating water excretion and hence blood osmolality, magnocellular AVP neurons are regulated by two temporally distinct signals: 1) slow systemic signals that convey systemic osmolality information, and 2) rapid ‘presystemic’ signals that anticipate future osmotic challenges.
    [Show full text]
  • Specifications of Approved Drug Compound Library
    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
    [Show full text]
  • Assessment of Novel Drugs for Treating Preterm Labour Using a Translational Model
    Assessment of novel drugs for treating preterm labour using a translational model A thesis submitted to the University of Manchester for the degree of Doctor of Philosophy in the Faculty of Biology, Medicine and Health 2020 Ammar Ahmed Mohammed School of Health Sciences Division of Pharmacy and Optometry 1 Table of contents Table of contents .............................................................................................. 2 List of Figures .................................................................................................................. 9 List of Tables ................................................................................................................. 20 List of abbreviations ..................................................................................................... 22 Publications .................................................................................................................... 27 Abstract .. ....................................................................................................................... 28 Declaration ..................................................................................................................... 29 Acknowledgements ........................................................................................................ 30 Dedication ...................................................................................................................... 32 1 Chapter 1: ...........................................................................................
    [Show full text]
  • Vaptans: a New Option in the Management of Hyponatremia
    [Downloaded free from http://www.ijabmr.org on Monday, August 18, 2014, IP: 218.241.189.21] || Click here to download free Android application for this journal Educational Forum Vaptans: A new option in the management of hyponatremia Suruchi Aditya, Aditya Rattan1 Department of Pharmacology, Dr. Harvansh Singh Judge Institute of Dental Sciences, Chandigarh. 1Consultant Cardiologist, Heartline, Panchkula, Haryana, India Abstract Arginine vasopressin (AVP) plays an important role in water and sodium homeostasis. It acts via three receptor subtypes— V1a, V 1b, and V2—distributed widely throughout the body. Vaptans are nonpeptide vasopressin receptor antagonists (VRA). By property of aquaresis, VRAs offer a novel therapy of water retention. Conivaptan is a V1a/V2 nonselective VRA approved for euvolemic and hypervolemic hyponatremia. Tolvaptan is the first oral VRA. Other potential uses of this new class of drugs include congestive heart failure (CHF), cirrhosis of liver, syndrome of inappropriate secretion of antidiuretic hormone, polycystic kidney disease, and so on. These novel drugs score over diuretics as they are not associated with electrolyte abnormalities. Though much remains to be elucidated before the VRAs are applied clinically, the future holds much promise. Key words: Aquaresis, hyponatremia, syndrome of inappropriate antidiuretic hormone secretion, vaptan, vasopressin receptor antagonists Introduction hormone (ADH), renin angiotensin aldosterone system (RAAS), sympathetic nervous system (SNS), and thirst help Hyponatremia, one of the most common electrolyte to control water homeostasis in the body and keep plasma abnormalities in hospitalized patients, is defined as serum osmolality between 275 and 290 mOsm/kg water. sodium concentration <135 mEq/L. Its prevalence is one in five of all hospitalized patients.[1] Recent clinical data suggests Hyponatremia can be associated with low, normal, or high that hyponatremia is not only a marker of disease severity but tonicity.
    [Show full text]
  • Hypernatremia: 2 Months Back When He Had Progressive Decrease in Vision (Right > Left)
    Correspondence to increased intrathoracic pressure and central radiologist regarding vascular injury when there is venous pressure, decreased venous return from the refractory hypotension so that necessary steps can be brain and increased ICP[4] taken to identify and treat iatrogenic complications that • Patients with aneurysmal SAH have disturbed might compound the pre‑existing morbidity. autoregulation of cerebral blood flow. Hence, intraoperative hypotension of any cause has an REFERENCES adverse effect on the outcome of SAH[5,6] • Patients with poor grade SAH (Fischer III/IV) and 1. Young WL, Pile-Spellman J. Anesthetic considerations for interventional Neuroradiolgy (Review). Anesthesiology angiographic evidence of vasospasm which our 1994;80:427-56. patient had, are at risk for cerebral hypoperfusion 2. Varma MK, Price K, Jayakrishnan V, Manickam B, Kessell G. because of impaired cerebral autoregulation and Anaesthetic considerations for interventional neuroradiology. thus intraoperative hypotension and cerebral Br J Anaesth 2007;99:75-85. [6,7] 3. Kent KC, Moscucci M, Mansour KA, Dimattia S, Gallagher S, hypoperfusion compounds the poor outcome Kuntz R, et al. Retroperitoneal hematoma after cardiac • Blood loss leading to severe anaemia (Hb 3.8 g%) catheterization: Prevalence, risk factors, and optimal during the procedure might have lead to decreased management. J Vasc Surg 1994;20:905-10. oxygen‑carrying capacity of blood and further 4. De Laet I, Citerio G, Malbrain ML. The influence of exacerbate the hypoxic injury to brain. intraabdominal hypertension on the central nervous system: Current insights and clinical recommendations, is it all in the Thus a combination of age, poor grade SAH, diffuse head? Acta Clin Belg Suppl 2007;1:89-97.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • New Approaches of the Hyponatremia Treatment in the Elderly – an Update
    FARMACIA, 2020, Vol. 68, 3 https://doi.org/10.31925/farmacia.2020.3.5 REVIEW NEW APPROACHES OF THE HYPONATREMIA TREATMENT IN THE ELDERLY – AN UPDATE ALICE BĂLĂCEANU 1,2#, SECIL OMER 1,2, SILVIU ADRIAN MARINESCU 1,3*, SILVIU MIREL PIȚURU 1#, ȘERBAN DUMITRACHE 2#, DANIELA ELENA POPA 1, ANDREEA ANTONIA GHEORGHE 2, SIRAMONA POPESCU 3, CĂTĂLIN BEJINARIU 3, OCTAV GINGHINĂ 1,2, CARMEN GIUGLEA 1,2 1“Carol Davila” University of Medicine and Pharmacy, 37 Dionisie Lupu Street, 020021, Bucharest, Romania 2“Sf. Ioan” Clinical Emergency Hospital, 13 Vitan-Bârzești Road, 042122, Bucharest, Romania 3“Bagdasar Arseni” Clinical Emergency Hospital, 12 Berceni Road, 041915, Bucharest, Romania *corresponding author: [email protected] #Authors with equal contribution. Manuscript received: December 2019 Abstract Hyponatremia (hNa) is a frequently common imbalance in the elderly hospitalized patients. It is often correlated with elevated plasma quantities of arginine vasopressin (AVP, the antidiuretic hormone) and namely it depicts a water surplus in order to prevail sodium levels. It can conduct, in a comprehensive range, to detrimental changes that can affect the entire health status, especially the central nervous system, thus increasing the mortality and morbidity of hospitalized patients in care units. The inherent treatment of hNa, mainly of the chronic form, requires the correction of serum sodium concentrations at the appropriate rate, because, augmenting it at a warp speed, it can determine permanent or fatal neurologic sequelae. In this regard, the therapy for hNa may be enlightened by egressing therapies that include vasopressin V2 and V1a receptors antagonists, with the principal role of encouraging aquaresis and rise the serum sodium levels, alongside with the electrolyte- sparing discharge of free water.
    [Show full text]
  • The Syndrome of Inappropriate Antidiuretic Hormone: Current and Future Management Options
    European Journal of Endocrinology (2010) 162 S13–S18 ISSN 0804-4643 The syndrome of inappropriate antidiuretic hormone: current and future management options Mark Sherlock and Chris J Thompson1 Centre for Endocrinology, Diabetes and Metabolism, School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, B15 2TT, UK and 1Academic Department of Diabetes and Endocrinology, Beaumont Hospital and RCSI Medical School, Beaumont Road, Dublin 9, Ireland (Correspondence should be addressed to C J Thompson; Email: [email protected]) Abstract Hyponatraemia is the commonest electrolyte abnormality, and syndrome of inappropriate antidiuretic hormone (SIADH) is the most frequent underlying pathophysiology. Hyponatraemia is associated with significant morbidity and mortality, and as such appropriate treatment is essential. Treatment options for SIADH include fluid restriction, demeclocycline, urea, frusemide and saline infusion, all of which have their limitations. The introduction of the vasopressin-2 receptor antagonists has allowed clinicians to specifically target the underlying pathophysiology of SIADH. Initial studies have shown good efficacy and safety profiles in the treatment of mild to moderate hyponatraemia. However, studies assessing the efficacy and safety of these agents in acute severe symptomatic hyponatraemia are awaited. Furthermore, the cost of these agents at present may limit their use. European Journal of Endocrinology 162 S13–S18 Introduction diagnosis of SIADH and the differentiation from other causes of hyponatraemia is the first essential step in The previous article in this supplement established determining appropriate treatment. Diagnostic criteria that hyponatraemia due to syndrome of inappropriate for SIADH are included in Table 1 (10). In this article, antidiuretic hormone (SIADH) is associated with we review the existing treatments available for the significant morbidity (1), mortality (2–5) and increased management of SIADH and discuss the potential impact length of hospital stay (6).
    [Show full text]
  • I Regulations
    23.2.2007 EN Official Journal of the European Union L 56/1 I (Acts adopted under the EC Treaty/Euratom Treaty whose publication is obligatory) REGULATIONS COUNCIL REGULATION (EC) No 129/2007 of 12 February 2007 providing for duty-free treatment for specified pharmaceutical active ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation and specified products used for the manufacture of finished pharmaceuticals and amending Annex I to Regulation (EEC) No 2658/87 THE COUNCIL OF THE EUROPEAN UNION, (4) In the course of three such reviews it was concluded that a certain number of additional INNs and intermediates used for production and manufacture of finished pharmaceu- ticals should be granted duty-free treatment, that certain of Having regard to the Treaty establishing the European Commu- these intermediates should be transferred to the list of INNs, nity, and in particular Article 133 thereof, and that the list of specified prefixes and suffixes for salts, esters or hydrates of INNs should be expanded. Having regard to the proposal from the Commission, (5) Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Common Customs Tariff (1) established the Combined Nomenclature Whereas: (CN) and set out the conventional duty rates of the Common Customs Tariff. (1) In the course of the Uruguay Round negotiations, the Community and a number of countries agreed that duty- (6) Regulation (EEC) No 2658/87 should therefore be amended free treatment should be granted to pharmaceutical accordingly, products falling within the Harmonised System (HS) Chapter 30 and HS headings 2936, 2937, 2939 and 2941 as well as to designated pharmaceutical active HAS ADOPTED THIS REGULATION: ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation, specified salts, esters or hydrates of such INNs, and designated inter- Article 1 mediates used for the production and manufacture of finished products.
    [Show full text]
  • Eudract Number: 2018-000477-77 (Version: 2; Version Date: 31 Jul 2018)
    Eudract Number: 2018-000477-77 (Version: 2; Version Date: 31 Jul 2018) CLINICAL NO PROFIT PROTOCOL EUDRACT NUMBER: 2018-000477-77 TITLE: Metformin versus Tolvaptan in adults with Autosomal Dominant Polycystic Kidney Disease (ADPKD): a phase 3a, independent, multi- centre, 2 parallel arms randomized controlled trial STUDY NAME: METROPOLIS VERSION: 2 VERSION DATE: 31 July 2018 Page 1 of 111 Eudract Number: 2018-000477-77 (Version: 2; Version Date: 31 Jul 2018) SPONSOR Name: Università degli Studi di Bari Dipartimento dell’Emergenza e dei Trapianti di organi (D.E.T.O.) Address: Piazza G.Cesare n.11-Policlinico- 70124 Bari Phone: +39 0805478627- Ufficio protocollo + 39080 5478614 E mail : [email protected] Signature ( per lo sponsor ) Prof. Loreto Gesualdo CHAIRMAN/STUDY Name: Prof. Loreto Gesualdo -Direttore U.O. COORDINATOR Nefrologia Universitaria – Azienda Policlinico di Bari Address: Piazza G.Cesare n.11 70124 Bari Phone: + 39 080 5594041 Fax: + 39 080 5478675 Email: [email protected] Prof. Loreto Gesualdo PRINCIPAL/COORDINATING Name: Prof. Loreto Gesualdo - Direttore U.O. INVESTIGATOR Nefrologia Universitaria – Azienda Policlinico di Bari Address: Piazza G. Cesare n.11 70124 Bari Phone: + 39 080 5594041 Fax: 39 080 5478675 Email: [email protected] Prof. Loreto Gesualdo MEDICAL WRITING Name: Prof. Loreto Gesualdo; Name: Dr. Giovanni Piscopo Page 2 of 111 Eudract Number: 2018-000477-77 (Version: 2; Version Date: 31 Jul 2018) TABLE OF CONTENTS A. LIST OF ABBREVIATIONS ....................................................................................
    [Show full text]
  • "Hyponatremia"[Text Word]) OR "Hyponatremic"[Text Word]
    SYSTEMATIC MAPPING SEARCH STRATEGY PubMed "Hyponatremia"[Mesh] ("hyponatremia"[Text Word]) OR "hyponatremic"[Text Word] ("euvolemic"[Text Word]) OR "hypervolemic"[Text Word] "Inappropriate ADH Syndrome"[Mesh] "antidiuretic hormone"[Text Word] "Heart Failure"[Mesh] "heart failure"[Text Word] "Liver Cirrhosis"[Mesh] ("cirrhosis"[Text Word]) OR "ascites"[Text Word] "Receptors, Vasopressin"[Mesh] "Antidiuretic Hormone Receptor Antagonists"[Mesh] ("v2"[Text Word]) OR "v1a"[Text Word] (("vaptans"[Text Word]) OR "aquaretic"[Text Word]) OR "aquaresis"[Text Word] ("tolvaptan"[Text Word]) OR "opc 41061"[Text Word] ("conivaptan"[Text Word]) OR "ym087"[Text Word] ("satavaptan"[Text Word]) OR "sr121463b"[Text Word] ("lixivaptan"[Text Word]) OR "vpa 985"[Text Word] ("mozavaptan"[Text Word]) OR "opc 31260"[Text Word] "Clinical Trials as Topic"[Majr] "Controlled Clinical Trials as Topic"[Majr] "Randomized Controlled Trials as Topic"[Majr] "Clinical Trial" [Publication Type] "Controlled Clinical Trial" [Publication Type] "Randomized Controlled Trial" [Publication Type] "Random Allocation"[Majr] (("random"[Text Word]) OR "randomly"[Text Word]) OR "randomization"[Text Word] "trial"[Text Word] "Double-Blind Method"[Majr] "Single-Blind Method"[Majr] "double blind"[Text Word] "single blind"[Text Word] "open label"[Text Word] "Placebos"[Majr] "placebo"[Text Word] "post hoc"[Text Word] "subgroup"[Text Word] "extension"[Text Word] OvidMedline(R) Journals@Ovid (Sumarios y Resúmenes todas las Revistas Ovid), Revistas Subscritas a Texto Completo por Sacyl, OvidMEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citantions, Ovid MEDLINE(R) Daily, Ovid MEDLINE and Versions(R) exp Hyponatremia/ hyponatr$.tw. (euvolemic or hypervolemic).tw. exp Inappropriate ADH Syndrome/ (antidiuretic adj hormone).tw. exp Heart Failure/ (heart adj failure).tw. exp Liver Cirrhosis/ (cirrhosis or ascites).tw.
    [Show full text]
  • Sodium Excretion in Response to Vasopressin and Selective Vasopressin Receptor Antagonists
    BASIC RESEARCH www.jasn.org Sodium Excretion in Response to Vasopressin and Selective Vasopressin Receptor Antagonists Julie Perucca,*† Daniel G. Bichet,‡ Pascale Bardoux,* Nadine Bouby,*† and Lise Bankir*† *INSERM, Unite´ 872, and †UMRS 872, Universite´ Paris Descartes, Centre de Recherche des Cordeliers, Paris, France; and ‡Service de Ne´phrologie, Hoˆpital du Sacre´-Coeur, De´partement de Me´decine, Universite´ de Montre´al, Montre´al, Que´bec, Canada ABSTRACT The mechanisms by which arginine vasopressin (AVP) exerts its antidiuretic and pressor effects, via activation of V2 and V1a receptors, respectively, are relatively well understood, but the possible associated effects on sodium handling are a matter of controversy. In this study, normal conscious Wistar rats were acutely administered various doses of AVP, dDAVP (V2 agonist), furosemide, or the following selective non-peptide receptor antagonists SR121463A (V2 antagonist) or SR49059 (V1a antagonist). Urine flow and sodium excretion rates in the next 6 h were compared with basal values obtained on the previous day, after vehicle treatment, using each rat as its own control. The rate of sodium excretion decreased with V2 agonism and increased with V2 antagonism in a dose-dependent manner. However, for comparable increases in urine flow rate, the V2 antagonist induced a natriuresis 7-fold smaller than did furosemide. Vasopressin reduced sodium excretion at 1 ␮g/kg but increased it at doses Ͼ5 ␮g/kg, an effect that was abolished by the V1a antagonist. Combined V2 and V1a effects of endogenous vasopressin can be predicted to vary largely according to the respective levels of vasopressin in plasma, renal medulla (acting on interstitial cells), and urine (acting on V1a luminal receptors).
    [Show full text]